World Journal of Surgery

, Volume 34, Issue 1, pp 70–78 | Cite as

A Critical Evaluation of Risk Factors for Complications After Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Colorectal Peritoneal Carcinomatosis

Article

Abstract

Background

Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) has demonstrated improved survival in selected patients with colorectal peritoneal carcinomatosis (CRPC). This treatment modality is associated with relatively high rates of perioperative morbidity and mortality. This study evaluated the clinical and treatment-related risk factors for perioperative morbidity and mortality in patients with CRPC who underwent CRS and PIC.

Methods

Sixty-three consecutive patients who underwent CRS and PIC for CRPC were evaluated. Adverse events were rated from grades I to V with increasing severity. Clinical and treatment-related risk factors for grades III and IV/V morbidity were determined.

Results

There were no perioperative deaths (0%). The grades III and IV morbidity rates were 14 and 17%, respectively. A peritoneal cancer index >12 (p = 0.019), transfusion >4 units (p = 0.028), number of peritonectomy procedures >3 (p = 0.013), left upper quadrant peritonectomy procedure (p < 0.001), and number of primary colonic anastomosis >1 (p = 0.004) were associated with grade IV morbidity on univariate analysis. Only left upper quadrant procedure was associated with grade IV morbidity on multivariate analysis (p = 0.002). Only number of primary colonic anastomosis >1 (p = 0.037) was associated with grade III morbidity on univariate analysis. This also was associated with grade III morbidity on multivariate analysis (p = 0.028).

Conclusions

CRS and PIC has an acceptable risk of perioperative morbidity in carefully selected patients with CRPC. Patients who require extensive surgery have the highest risk for a severe adverse event. Preoperative evaluation of patients is essential to improve perioperative outcome.

References

  1. 1.
    Glehen O, Osinsky D, Beaujard AC, Gilly FN (2003) Natural history of peritoneal carcinomatosis from nongynecologic malignancies. Surg Oncol Clin N Am 12(3):729–739 (xiii)CrossRefPubMedGoogle Scholar
  2. 2.
    Jayne DG, Fook S, Loi C, Seow-Choen F (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89(12):1545–1550CrossRefPubMedGoogle Scholar
  3. 3.
    Schott A, Vogel I, Krueger U et al (1998) Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. Ann Surg 227(3):372–379CrossRefPubMedGoogle Scholar
  4. 4.
    Yan TD, Black D, Savady R, Sugarbaker PH (2006) Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 24(24):4011–4019CrossRefPubMedGoogle Scholar
  5. 5.
    Yan TD, Morris DL (2008) Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care? Ann Surg 248(5):829–835PubMedGoogle Scholar
  6. 6.
    Elias D, Lefevre JH, Chevalier J et al (2009) Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 27(5):681–685CrossRefPubMedGoogle Scholar
  7. 7.
    Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21(20):3737–3743CrossRefPubMedGoogle Scholar
  8. 8.
    Glehen O, Kwiatkowski F, Sugarbaker PH et al (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22(16):3284–3292CrossRefPubMedGoogle Scholar
  9. 9.
    Hansson J, Graf W, Pahlman L et al (2009) Postoperative adverse events and long-term survival after cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 35(2):202–208PubMedGoogle Scholar
  10. 10.
    Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FA (2004) Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 85(2):61–67CrossRefPubMedGoogle Scholar
  11. 11.
    Elias D, Goere D, Blot F et al (2007) Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43°C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol 14(6):1818–1824CrossRefPubMedGoogle Scholar
  12. 12.
    Stephens AD, Alderman R, Chang D et al (1999) Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 6(8):790–796CrossRefPubMedGoogle Scholar
  13. 13.
    Kusamura S, Younan R, Baratti D et al (2006) Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 106(5):1144–1153CrossRefPubMedGoogle Scholar
  14. 14.
    Glehen O, Osinsky D, Cotte E et al (2003) Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 10(8):863–869CrossRefPubMedGoogle Scholar
  15. 15.
    Jacquet P, Stephens AD, Averbach AM et al (1996) Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 77(12):2622–2629CrossRefPubMedGoogle Scholar
  16. 16.
    Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–374PubMedGoogle Scholar
  17. 17.
    ASA (1963) New classification of physical status. Anesthesiology 24:111–114Google Scholar
  18. 18.
    Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29–42PubMedCrossRefGoogle Scholar
  19. 19.
    Elias D, Blot F, El Otmany A et al (2001) Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 92(1):71–76CrossRefPubMedGoogle Scholar
  20. 20.
    Kecmanovic DM, Pavlov MJ, Ceranic MS et al (2005) Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy. Eur J Surg Oncol 31(2):147–152CrossRefPubMedGoogle Scholar
  21. 21.
    Pestieau SR, Sugarbaker PH (2000) Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. Dis Colon Rectum 43(10):1341–1348CrossRefPubMedGoogle Scholar
  22. 22.
    Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743CrossRefPubMedGoogle Scholar
  23. 23.
    Vamvakas EC (2002) Possible mechanisms of allogeneic blood transfusion-associated postoperative infection. Transfus Med Rev 16(2):144–160CrossRefPubMedGoogle Scholar
  24. 24.
    Saxena A, Yan TD, Chua TC et al (2009) Risk factors for massive blood transfusion in cytoreductive surgery: a multivariate analysis of 243 procedures. Ann Surg Oncol 16(8):2195–2203CrossRefPubMedGoogle Scholar
  25. 25.
    Hill GE, Frawley WH, Griffith KE et al (2003) Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. J Trauma 54(5):908–914CrossRefPubMedGoogle Scholar
  26. 26.
    Yan TD, Links M, Fransi S et al (2007) Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy—a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol 14(8):2270–2280CrossRefPubMedGoogle Scholar
  27. 27.
    Smeenk RM, Verwaal VJ, Zoetmulder FA (2007) Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 94(11):1408–1414CrossRefPubMedGoogle Scholar
  28. 28.
    Kusamura S, Baratti D, Younan R et al (2007) Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. Ann Surg Oncol 14(9):2550–2558CrossRefPubMedGoogle Scholar
  29. 29.
    Copeland GP, Jones D, Walters M (1991) POSSUM: a scoring system for surgical audit. Br J Surg 78(3):355–360CrossRefPubMedGoogle Scholar
  30. 30.
    Al-Homoud S, Purkayastha S, Aziz O et al (2004) Evaluating operative risk in colorectal cancer surgery: ASA and POSSUM-based predictive models. Surg Oncol 13(2–3):83–92CrossRefPubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2009

Authors and Affiliations

  • Akshat Saxena
    • 1
  • Tristan D. Yan
    • 1
  • David L. Morris
    • 1
  1. 1.Department of Surgery, St George HospitalUniversity of New South WalesSydneyAustralia

Personalised recommendations